{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T06:27:17Z","timestamp":1782455237458,"version":"3.54.5"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T00:00:00Z","timestamp":1723075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T00:00:00Z","timestamp":1723075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neurolymphomatosis refers to infiltration of the peripheral nervous system (PNS) by non-Hodgkin lymphoma (NHL). Diagnostic intervals in neurolymphomatosis and factors delaying diagnosis have not been evaluated. We therefore aimed to analyze diagnostic intervals in a large cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The quality control database at Yale Cancer Center, Section of Neuro-Oncology, was searched for neurolymphomatosis cases diagnosed between 2001 and 2021. Univariate analyses were performed to identify parameters influencing diagnostic intervals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We identified 22 neurolymphomatosis cases including 7 with primary and 15 with secondary disease, which occurred a median (range: 4\u2013144) of 16 months after initial NHL diagnosis. Patients typically presented with painful polyneuropathy (73%), that was asymmetrical and rapidly progressive. Diagnosis was based on PNS biopsy (50%) or integration of neuroimaging findings (50%) with NHL history and diagnostic cerebrospinal fluid examinations. Median interval from symptom onset to diagnosis was 3 months (range: 1\u201312). Secondary neurolymphomatosis compared to primary disease (median 2 vs. 6 months,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02), and cases with rapidly-progressive asymmetrical neuropathy as opposed to other presentations (median 2 vs. 6 months;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) were diagnosed earlier. Upfront conventional CT compared to other modalities (median 2 vs. 5 months\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.04) and nerve root localization as opposed to other disease sites (median 1.5 vs. 4 months;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.04) delayed diagnosis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>NL type and localization, neuropathy course and distribution, and imaging modality selected for initial evaluation influence diagnostic intervals in neurolymphomatosis. Knowledge of this rare entity is critical for early suspicion, and diagnosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11060-024-04792-2","type":"journal-article","created":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T10:02:42Z","timestamp":1723111362000},"page":"309-317","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Factors influencing timely diagnosis in neurolymphomatosis"],"prefix":"10.1007","volume":"170","author":[{"given":"Sofia","family":"Doubrovinskaia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Egert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Karschnia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg T.","family":"Scheffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin-Leon","family":"Traub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Galluzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Huttner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert K.","family":"Fulbright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim M.","family":"Baehring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon D.","family":"Kaulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,8]]},"reference":[{"key":"4792_CR1","doi-asserted-by":"crossref","unstructured":"Baehring JM, Damek D, Martin EC, Betensky RA, Hochberg FH (2003) Neurolymphomatosis Neuro Oncol 5(2):104\u2013115","DOI":"10.1093\/neuonc\/5.2.104"},{"issue":"24","key":"4792_CR2","doi-asserted-by":"publisher","first-page":"5005","DOI":"10.1182\/blood-2009-12-258210","volume":"115","author":"S Grisariu","year":"2010","unstructured":"Grisariu S, Avni B, Batchelor TT, van den Bent MJ, Bokstein F, Schiff D et al (2010) Neurolymphomatosis: an International Primary CNS Lymphoma Collaborative Group report. Blood 115(24):5005\u20135011","journal-title":"Blood"},{"issue":"5","key":"4792_CR3","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/PPO.0b013e31826c5ad5","volume":"18","author":"JM Baehring","year":"2012","unstructured":"Baehring JM, Batchelor TT (2012) Diagnosis and management of neurolymphomatosis. Cancer J 18(5):463\u2013468","journal-title":"Cancer J"},{"issue":"18","key":"4792_CR4","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1212\/WNL.0000000000004600","volume":"89","author":"LD Kaulen","year":"2017","unstructured":"Kaulen LD, Foss FM, Fulbright RK, Huttner A, Baehring JM (2017) Neurolymphomatosis of the thoracic sympathetic chain. Neurology 89(18):1926\u20131927","journal-title":"Neurology"},{"key":"4792_CR5","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209698","author":"LD Kaulen","year":"2024","unstructured":"Kaulen LD, Hielscher T, Doubrovinskaia S et al (2024) Clinical Presentation, Management, and Outcome in Neurolymphomatosis: A Systematic Review. Neurology103(4):e209698 https:\/\/doi.org\/10.1212\/WNL.0000000000209698","journal-title":"Neurology"},{"issue":"7","key":"4792_CR6","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1136\/jnnp.2007.125930","volume":"79","author":"K Viala","year":"2008","unstructured":"Viala K, B\u00e9hin A, Maisonobe T, L\u00e9ger JM, Stojkovic T, Davi F et al (2008) Neuropathy in lymphoma: a relationship between the pattern of neuropathy, type of lymphoma and prognosis? J Neurol Neurosurg Psychiatry 79(7):778\u2013782","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"20","key":"4792_CR7","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1001\/jama.2015.13611","volume":"314","author":"BC Callaghan","year":"2015","unstructured":"Callaghan BC, Price RS, Feldman EL (2015) Distal symmetric polyneuropathy: a review. JAMA 314(20):2172\u20132181","journal-title":"JAMA"},{"issue":"28","key":"4792_CR8","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1200\/JCO.20.01399","volume":"38","author":"CL Loprinzi","year":"2020","unstructured":"Loprinzi CL, Lacchetti C, Bleeker J, Cavaletti G, Chauhan C, Hertz DL et al (2020) Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in survivors of adult cancers: ASCO Guideline Update. J Clin Oncol 38(28):3325\u20133348","journal-title":"J Clin Oncol"},{"issue":"11","key":"4792_CR9","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1200\/JCO.1989.7.11.1630","volume":"7","author":"TA Lister","year":"1989","unstructured":"Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC et al (1989) Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin\u2019s disease: Cotswolds meeting. J Clin Oncol 7(11):1630\u20131636","journal-title":"J Clin Oncol"},{"issue":"27","key":"4792_CR10","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-hodgkin lymphoma: the Lugano classification. J Clin Oncol 32(27):3059\u20133068","journal-title":"J Clin Oncol"},{"issue":"5","key":"4792_CR11","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1182\/bloodadvances.2020003666","volume":"5","author":"A Khurana","year":"2021","unstructured":"Khurana A, Novo M, Nowakowski GS, Ristow KM, Spinner RJ, Hunt CH et al (2021) Clinical manifestations of, diagnostic approach to, and treatment of neurolymphomatosis in the Rituximab era. Blood Adv 5(5):1379\u20131387","journal-title":"Blood Adv"},{"key":"4792_CR12","doi-asserted-by":"crossref","unstructured":"Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, M\u00fceller SP et al (2014) Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol.;32(27):3048-58","DOI":"10.1200\/JCO.2013.53.5229"},{"issue":"1","key":"4792_CR13","doi-asserted-by":"publisher","first-page":"e80","DOI":"10.1016\/S2352-3026(20)30365-3","volume":"8","author":"SF Barrington","year":"2021","unstructured":"Barrington SF, Trotman J (2021) The role of PET in the first-line treatment of the most common subtypes of non-hodgkin lymphoma. Lancet Haematol 8(1):e80\u2013e93","journal-title":"Lancet Haematol"},{"issue":"4","key":"4792_CR14","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1136\/jnnp.69.4.442","volume":"69","author":"CM Gabriel","year":"2000","unstructured":"Gabriel CM, Howard R, Kinsella N, Lucas S, McColl I, Saldanha G et al (2000) Prospective study of the usefulness of sural nerve biopsy. J Neurol Neurosurg Psychiatry 69(4):442\u2013446","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"4792_CR15","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1136\/jnnp.2007.116368","volume":"78","author":"DA Hilton","year":"2007","unstructured":"Hilton DA, Jacob J, Househam L, Tengah C (2007) Complications following sural and peroneal nerve biopsies. J Neurol Neurosurg Psychiatry 78(11):1271\u20131272","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"4792_CR16","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1080\/02841860500256272","volume":"44","author":"IS Haldorsen","year":"2005","unstructured":"Haldorsen IS, Espeland A, Larsen JL, Mella O (2005) Diagnostic delay in primary central nervous system lymphoma. Acta Oncol 44(7):728\u2013734","journal-title":"Acta Oncol"},{"issue":"3","key":"4792_CR17","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s11060-020-03547-z","volume":"148","author":"R Velasco","year":"2020","unstructured":"Velasco R, Mercadal S, Vidal N, Ala\u00f1\u00e1 M, Barcel\u00f3 MI, Ib\u00e1\u00f1ez-Juli\u00e1 MJ et al (2020) Diagnostic delay and outcome in immunocompetent patients with primary central nervous system lymphoma in Spain: a multicentric study. J Neurooncol 148(3):545\u2013554","journal-title":"J Neurooncol"},{"issue":"11","key":"4792_CR18","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1038\/sj.bjc.6602587","volume":"92","author":"VL Allgar","year":"2005","unstructured":"Allgar VL, Neal RD (2005) Delays in the diagnosis of six cancers: analysis of data from the National Survey of NHS patients: Cancer. Br J Cancer 92(11):1959\u20131970","journal-title":"Br J Cancer"},{"issue":"1","key":"4792_CR19","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s42466-020-00064-2","volume":"2","author":"HC Lehmann","year":"2020","unstructured":"Lehmann HC, Wunderlich G, Fink GR, Sommer C (2020) Diagnosis of peripheral neuropathy. Neurol Res Pract 2(1):20","journal-title":"Neurol Res Pract"},{"key":"4792_CR20","doi-asserted-by":"publisher","first-page":"g7400","DOI":"10.1136\/bmj.g7400","volume":"349","author":"G Lyratzopoulos","year":"2014","unstructured":"Lyratzopoulos G, Wardle J, Rubin G (2014) Rethinking diagnostic delay in cancer: how difficult is the diagnosis? BMJ 349:g7400","journal-title":"BMJ"},{"key":"4792_CR21","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1200\/EDBK_236857","volume":"39","author":"P Selby","year":"2019","unstructured":"Selby P, Popescu R, Lawler M, Butcher H, Costa A (2019) The Value and Future developments of Multidisciplinary Team Cancer Care. Am Soc Clin Oncol Educ Book 39:332\u2013340","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"1","key":"4792_CR22","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41572-019-0092-1","volume":"5","author":"EL Feldman","year":"2019","unstructured":"Feldman EL, Callaghan BC, Pop-Busui R, Zochodne DW, Wright DE, Bennett DL et al (2019) Diabetic neuropathy. Nat Reviews Disease Primers 5(1):41","journal-title":"Nat Reviews Disease Primers"},{"issue":"6","key":"4792_CR23","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S1474-4422(12)70065-0","volume":"11","author":"BC Callaghan","year":"2012","unstructured":"Callaghan BC, Cheng HT, Stables CL, Smith AL, Feldman EL (2012) Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol 11(6):521\u2013534","journal-title":"Lancet Neurol"},{"issue":"4","key":"4792_CR24","doi-asserted-by":"publisher","first-page":"811","DOI":"10.3174\/ajnr.A4173","volume":"36","author":"W Brinjikji","year":"2015","unstructured":"Brinjikji W, Luetmer PH, Comstock B, Bresnahan BW, Chen LE, Deyo RA et al (2015) Systematic literature review of imaging features of spinal degeneration in asymptomatic populations. AJNR Am J Neuroradiol 36(4):811\u2013816","journal-title":"AJNR Am J Neuroradiol"},{"issue":"5","key":"4792_CR25","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1182\/blood.2020010137","volume":"138","author":"M Gupta","year":"2021","unstructured":"Gupta M, Burns EJ, Georgantas NZ, Thierauf J, Nayyar N, Gordon A et al (2021) A rapid genotyping panel for detection of primary central nervous system lymphoma. Blood 138(5):382\u2013386","journal-title":"Blood"},{"issue":"9","key":"4792_CR26","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1200\/JCO.22.00826","volume":"41","author":"JA Mutter","year":"2023","unstructured":"Mutter JA, Alig SK, Esfahani MS, Lauer EM, Mitschke J, Kurtz DM et al (2023) Circulating tumor DNA profiling for detection, risk stratification, and classification of Brain Lymphomas. J Clin Oncol 41(9):1684\u20131694","journal-title":"J Clin Oncol"},{"issue":"4","key":"4792_CR27","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1158\/2159-8290.CD-20-1311","volume":"11","author":"C Alix-Panabi\u00e8res","year":"2021","unstructured":"Alix-Panabi\u00e8res C, Pantel K (2021) Liquid Biopsy: from Discovery to Clinical Application. Cancer Discov 11(4):858\u2013873","journal-title":"Cancer Discov"},{"issue":"3","key":"4792_CR28","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/bjh.17357","volume":"193","author":"AJM Ferreri","year":"2021","unstructured":"Ferreri AJM, Calimeri T, Lopedote P, Francaviglia I, Daverio R, Iacona C et al (2021) MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study. Br J Haematol 193(3):497\u2013505","journal-title":"Br J Haematol"},{"issue":"2","key":"4792_CR29","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1111\/bjh.17319","volume":"193","author":"LD Kaulen","year":"2021","unstructured":"Kaulen LD, Erson-Omay EZ, Henegariu O, Karschnia P, Huttner A, G\u00fcnel M et al (2021) Exome sequencing identifies SLIT2 variants in primary CNS lymphoma. Br J Haematol 193(2):375\u2013379","journal-title":"Br J Haematol"},{"issue":"3","key":"4792_CR30","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s00401-023-02613-w","volume":"146","author":"LD Kaulen","year":"2023","unstructured":"Kaulen LD, Denisova E, Hinz F, Hai L, Friedel D, Henegariu O et al (2023) Integrated genetic analyses of immunodeficiency-associated Epstein-Barr virus- (EBV) positive primary CNS lymphomas. Acta Neuropathol 146(3):499\u2013514","journal-title":"Acta Neuropathol"},{"issue":"11","key":"4792_CR31","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1007\/s11864-022-01016-5","volume":"23","author":"LD Kaulen","year":"2022","unstructured":"Kaulen LD, Baehring JM (2022) Treatment Options for Recurrent Primary CNS Lymphoma. Curr Treat Options Oncol 23(11):1548\u20131565","journal-title":"Curr Treat Options Oncol"},{"issue":"3","key":"4792_CR32","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1093\/neuonc\/noy193","volume":"21","author":"C Grommes","year":"2019","unstructured":"Grommes C, Nayak L, Tun HW, Batchelor TT (2019) Introduction of novel agents in the treatment of primary CNS lymphoma. Neuro Oncol 21(3):306\u2013313","journal-title":"Neuro Oncol"},{"issue":"1","key":"4792_CR33","first-page":"vdac051","volume":"4","author":"LD Kaulen","year":"2022","unstructured":"Kaulen LD, Gumbinger C, Hinz F, Kessler T, Winkler F, Bendszus M et al (2022) Intraventricular immune checkpoint inhibition with nivolumab in relapsed primary central nervous system lymphoma. Neurooncol Adv 4(1):vdac051","journal-title":"Neurooncol Adv"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-024-04792-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-024-04792-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-024-04792-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T02:03:24Z","timestamp":1768356204000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-024-04792-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,8]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["4792"],"URL":"https:\/\/doi.org\/10.1007\/s11060-024-04792-2","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,8]]},"assertion":[{"value":"31 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article was originally published under the subscription model but it is now published under an Open Access license.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}